Oasmia Pharmaceutical AB (STO: OASM) will present the follow-up results from its completed Phase III study with Apealea for treatment of ovarian cancer at the 2018 ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago, the company said on Thursday.

Apealea is a Cremophor EL- and albumin-free formulation of the well-known cytostatic paclitaxel combined with Oasmia's excipient technology XR17. Paclitaxel is one of the most widely used anticancer substances and is included in the standard of treatment for a variety of cancers, such as lung cancer, breast cancer and ovarian cancer.

Apealea has received orphan drug designation in the EU and the US.

The Phase III open, randomised, multi-centre study included 789 patients and aimed to compare the efficacy and safety between Apealea and Taxol, another paclitaxel-based product. Both were given in combination with carboplatin.

The follow-up results, which will be presented during the poster session for Gynecologic Cancer, will include overall survival (OS) and progression free survival (PFS).